Even before they check in to the hotel, every fighter, coach, cameraman, journalist and UFC employee arriving in Jacksonville, Florida, is immediately directed to a screening station.

A devastating elbow combination has seen Calvin Kattar beat Jeremy Stephens at UFC249 by a second round TKO.

Producer Karim Morani's daughter Zoa Morani donated her blood for plasmatherapy trials for COVID-19 treatment at Mumbai's Nair hospital. Zoa, who has recently recovered from coronavirus along with her father Karim Morani and sister Shaza Morani, took to Instagram to inform everyone about her blood donation. She also mentioned that any person who has recovered from COVID-19, can take part in the cause.

"Donated my blood today for the #plasmatherapy trials at #nairhospital.. it was fascinating!!! Always a silver lining i suppose... the team there was so enthusiastic and careful. There was a general physician on standby just incase of emergency and the equipment brand new and safe!!! All #Covid19 recovered people can be a part of this trial, to help others covid patients recover! Thank you Dr Jayanti Shastri and Dr Ramesh Waghmare for taking such good care of me.. hope this works #covidrecovery #IndiaFightsCorona," shared Zoa on Instagram on Saturday evening.

 

 

 

View this post on Instagram

Donated my blood today for the #plasmatherapy trials at #nairhospital .. it was fascinating !!! Always a silver lining i suppose ... the team there was so enthusiastic and careful. There was a general physician on standby just incase of emergency and the equipment brand new and safe !!! All #Covid19 recovered people can be a part of this trial , to help others covid patients recover ! Thank you Dr Jayanti Shastri and Dr Ramesh Waghmare for taking such good care of me .. hope this works 🤲🏽🤲🏽🤲🏽🤲🏽🤲🏽🤲🏽 #covidrecovery #IndiaFightsCorona They even gave me a certificate and 500 rs , Wont lie , i felt super cool today ☺ï¸Â

A post shared by Zoa💫 (@zoamorani) onMay 9, 2020 at 6:22am PDT

Zoa shared photographs from the hospital clicked during and after her blood donation.

She also informed in her post that her blood donation has been acknowledged with a certificate and a Rs-500 remittance by the hospital and she feels "super cool" about it!

Catch up on all the latest entertainment news and gossip here. Also, download the new mid-day Android and iOS apps.

Mid-Day is now on Telegram. Click here to join our channel (@middayinfomedialtd) and stay updated with the latest news

1. Zoa Morani Donates Blood For Covid-19 Plasmatherapy, Says "It Felt Super Cool"  News18
2. Zoa Morani donates blood for Covid-19 plasmatherapy: ‘They even gave me a certificate and Rs 500. Wont...  Hindustan Times
3. COVID-19 survivor Zoa Morani donates blood for plasma therapy  Jimmys Post
4. Karim Moranis daughter Zoa donates blood for plasma therapy trials  Geo News
5. Zoa Morani urges all Covid-19 recovered people to donate blood for plasma therapy trials  The News International
6. View Full coverage on Google News

The worst may now be over, but as one frontline doctor reveals in her latest diary, traumatised medics now have time to reflect on the life-and-death decisions taken in the heat of battle… 

The worst may now be over, but as one frontline doctor reveals in her latest diary, traumatised medics now have time to reflect on the life-and-death decisions taken in the heat of battle… 

Mumbai, May 10 () Nearly a month after recovering from the coronavirus, actor Zoa Morani says she has donated her blood plasma to do her bit in helping the patients currently suffering from the novel virus.The actor, who was quarantined and kept under medication in April, also urged those who have recovered from COVID-19 to donate their plasma."Donated my blood today for the Plasma therapy trials at Nair hospital. It was fascinating! Always a silver lining I suppose. The team there was so enthusiastic and careful. There was a general physician on standby just incase of emergency and the equipment brand new and safe (sic)," Zoa wrote on Instagram on Saturday.She thanked the doctors for taking care of her and hoped patients benefit from the donation."All #Covid19 recovered people can be a part

Nearly a month after recovering from the coronavirus, actor Zoa Morani says she has donated her blood plasma to do her bit in helping the patients currently suffering from the novel virus. The actor, who was quarantined and kept under medication in April, also urged those who have recovered from COVID-19 to donate their plasma. "Donated my blood today for the Plasma therapy trials at Nair hospital. It was fascinating! Always a silver lining I suppose. The team there was so enthusiastic and careful. There was a general physician on standby just incase of emergency and the equipment brand new and safe (sic)," Zoa wrote on Instagram on Saturday. She thanked the doctors for taking care of her and hoped patients benefit from the donation. "All #Covid19 recovered people can be a part of this trial, to help others covid patients recover! I hope this works #IndiaFightsCorona. They even gave me a certificate and Rs 500. Wont lie, I felt super cool today (sic)," she added. Zoa, along with her ..

The move came as more nations review restrictions on blood donations imposed during the 1980s HIV/AIDS crisis, with some countries imposing blanket bans, some waiting periods after gay sex, and others - like Italy - having no limitations at all.

Blood clots, which are responsible foir killing many people every year, can now be treated without needles, i.e by oral medication.

Actress Zoa Morani, who along with sister Shaza and father, film producer Karim Morani recovered from Covid-19 in April donated her blood for plasmatherapy.

Actress Zoa Morani, who had tested positive for Coronavirus in early April, has donated her blood for plasmatherapy trials, at the Nair Hospital in Mumbai on Saturday. Zoa took to her Instagram handle to share pictures where she can be seen

Actress Zoa Morani, who had tested positive for Coronavirus in early April, has donated her blood for plasmatherapy trials, at the Nair Hospital in Mumbai on Saturday. Zoa took to her Instagram handle to share pictures where she can be seen

As of today, there are 2,407,439 COVID-19 cases with 165,073 deaths. On a hopeful note, 625,202 have recovered. The virus outbreak that began in 2019 continues to cause casualties, while health experts around the globe are extensively working on developing a

As of today, there are 29435 confirmed cases of COVID-19 in India with 6869 recovered cases and 934 deaths. COVID-19 tends to become severe in patients who are old or have some pre-existing medical conditions. They are at higher risk of

Zoa shared photographs from the hospital clicked during and after her blood donation.

Zoa Morani donates blood in Mumbai for plasma therapy to help those af...

Producer Karim Morani's daughter Zoa Morani donated her blood for plasmatherapy trials for COVID-19 treatment at Mumbai's Nair hospital today.

Found in well preserved shale deposits the fossils are so detailed that scientists were able to determine they represent two previously unknown species.

The post Discovery of new prehistoric mosquitoes reveal these blood-suckers have changed little in 46 million years appeared first on Smithsonian Insider.

Sometime during the Middle Eocene a prehistoric mosquito slurped down a final blood meal then died and sank to the bottom of a pond in […]

The post Blood molecules preserved for millions of years in abdomen of fossil mosquito appeared first on Smithsonian Insider.

When the heat and humidity of the Washington, D.C. summer sends its residents scrambling for air conditioning and iced coffee, the animal care specialists at […]

The post How do National Zoo animals beat the heat? Bloodsicles and other frozen delicacies appeared first on Smithsonian Insider.

What is the average blood pressure of a geriatric sloth bear? Asia Trail keeper Stacey Tabellario is hoping to learn exactly that, as she trains […]

The post Measuring Sloth Bear Blood Pressure appeared first on Smithsonian Insider.

With net in hand and eyes peeled, Mauren Turcatel spent two-weeks last October chasing blood-thirsty predators through the Amazon jungle of Brazil. One-by-one they appeared […]

The post Blood-thirsty jungle horse-flies catch big chill from Smithsonian entomologist appeared first on Smithsonian Insider.

Source: Streetwise Reports   05/05/2020

Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ), which focuses on blood-related disorders, and global biopharmaceuticals firm Alexion Pharmaceuticals Inc. (ALXN:NASDAQ) announced that they have entered into a definitive merger agreement for Portola to be acquired by Alexion.

The acquisition is said to provide a key addition to Alexion's diversified commercial portfolio. The report indicated that the merger agreement has already been unanimously approved each of the company's boards of directors.

The report explained that "Portola's commercialized medicine, Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya^® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding."

Portola's President and CEO Scott Garland commented, "In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and apixaban within two minutes, reducing anti-Factor Xa activity by 92 percent...Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa. With their commitment to commercial excellence, together, we will be able to drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting."

Ludwig Hantson, Ph.D., CEO of Alexion, remarked, "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care...We believe Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban. By leveraging Alexion's strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."

The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. The purchase is subject to approval by a majority interest of Portola's common stockholders tendering their shares along with ordinary closing conditions and regulatory approvals. The company noted that "following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger."

Alexion is a global biopharmaceutical company based in Boston, Mass., with offices in 50 countries worldwide. The company states that it has been "the global leader in complement biology and inhibition for more than 20 years and that it has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder."

Portola is headquartered in South San Francisco, Calif., and is a commercial-stage biopharmaceutical company focused on treating patients with serious blood-related disorders. Specifically, the company is engaged in developing and commercializing novel therapeutics in order to advance the fields of thrombosis and other hematologic conditions. The firm listed that its first two commercialized products are Andexxa^® and Bevyxxa^® (betrixaban), and that it is also advancing and developing cerdulatinib, a SYK/JAK inhibitor for use in treatment of hematologic cancers.

Portola Pharmaceuticals started off the day with a market capitalization of around $609.0 million with approximately 78.5 million shares outstanding and a short interest of about 23.0%. PTLA shares opened 130% higher today at $17.85 (+$10.09, +130.03%) over yesterday's $7.85 closing price. The stock has traded today between $17.71 and $17.91 per share and is currently trading at $17.83 (+$10.07, +129.77%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Despite progress in recent decades, more than 10,000 alcohol-impaired driving fatalities occur each year in the U.S. To address this persistent problem, stakeholders -- from transportation systems to alcohol retailers to law enforcement -- should work together to implement policies and systems to eliminate these preventable deaths, says a new report from the National Academies of Sciences, Engineering, and Medicine.

Source: Streetwise Reports   05/05/2020

Commercial-stage biotechnology company Portola Pharmaceuticals Inc. (PTLA:NASDAQ), which focuses on blood-related disorders, and global biopharmaceuticals firm Alexion Pharmaceuticals Inc. (ALXN:NASDAQ) announced that they have entered into a definitive merger agreement for Portola to be acquired by Alexion.

The acquisition is said to provide a key addition to Alexion's diversified commercial portfolio. The report indicated that the merger agreement has already been unanimously approved each of the company's boards of directors.

The report explained that "Portola's commercialized medicine, Andexxa^® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya^® in Europe, is the first and only approved Factor Xa inhibitor reversal agent, and has demonstrated transformative clinical value by rapidly reversing the anticoagulant effects of Factor Xa inhibitors rivaroxaban and apixaban in severe and uncontrolled bleeding."

Portola's President and CEO Scott Garland commented, "In developing and launching Andexxa, Portola has established a strong foundation for changing the standard of care for patients receiving Factor Xa inhibitors that experience a major, life-threatening bleed. Andexxa rapidly reverses the pharmacologic effect of rivaroxaban and apixaban within two minutes, reducing anti-Factor Xa activity by 92 percent...Given their enhanced resources, global footprint and proven commercial expertise, we look forward to working with Alexion to maximize the value of Andexxa. With their commitment to commercial excellence, together, we will be able to drive stronger utilization of Andexxa, increase penetration and accelerate adoption in the critical care setting."

Ludwig Hantson, Ph.D., CEO of Alexion, remarked, "The acquisition of Portola represents an important next step in our strategy to diversify beyond C5. Andexxa is a strategic fit with our existing portfolio of transformative medicines and is well-aligned with our demonstrated expertise in hematology, neurology and critical care...We believe Andexxa has the potential to become the global standard of care for patients who experience life-threatening bleeds while taking Factor Xa inhibitors apixaban and rivaroxaban. By leveraging Alexion's strong operational and sales infrastructure and deep relationships in hospital channels, we are well positioned to expand the number of patients helped by Andexxa, while also driving value for shareholders."

The firms advised that "under the terms of the merger agreement, a subsidiary of Alexion will commence a tender offer to acquire all of the outstanding shares of Portola's common stock at a price of $18 per share in cash." Alexion plans to fund the purchase with existing cash on hand and the transaction is expected to close in Q3/20. The purchase is subject to approval by a majority interest of Portola's common stockholders tendering their shares along with ordinary closing conditions and regulatory approvals. The company noted that "following successful completion of the tender offer, Alexion will acquire all remaining shares not tendered in the offer at the same price of $18 per share through a merger."

Alexion is a global biopharmaceutical company based in Boston, Mass., with offices in 50 countries worldwide. The company states that it has been "the global leader in complement biology and inhibition for more than 20 years and that it has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor antibody-positive generalized myasthenia gravis and neuromyelitis optica spectrum disorder."

Portola is headquartered in South San Francisco, Calif., and is a commercial-stage biopharmaceutical company focused on treating patients with serious blood-related disorders. Specifically, the company is engaged in developing and commercializing novel therapeutics in order to advance the fields of thrombosis and other hematologic conditions. The firm listed that its first two commercialized products are Andexxa^® and Bevyxxa^® (betrixaban), and that it is also advancing and developing cerdulatinib, a SYK/JAK inhibitor for use in treatment of hematologic cancers.

Portola Pharmaceuticals started off the day with a market capitalization of around $609.0 million with approximately 78.5 million shares outstanding and a short interest of about 23.0%. PTLA shares opened 130% higher today at $17.85 (+$10.09, +130.03%) over yesterday's $7.85 closing price. The stock has traded today between $17.71 and $17.91 per share and is currently trading at $17.83 (+$10.07, +129.77%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Recent research into the impact of different levels of noise on 75 volunteers reveals that disturbed sleep caused by night-time aircraft noise can damage blood vessels and increase the levels of stress hormones. As these physical changes are potential pathways to high blood pressure, heart and circulatory disease over the long term, reducing night-time aircraft noise is important for preventing cardiovascular disease in people living near airports.

High blood pressure is linked to long-term exposure to traffic-related air pollution, new research suggests. After accounting for lifestyle factors, socioeconomic status and pre-existing health conditions, the researchers found that a rise in traffic emissions of nitrogen dioxide corresponded to a rise in blood pressure of exposed individuals.

In Mexico, a drug cartel is extorting money from avocado producers and killing those who won’t pay. There’s no perfect way to avoid buying them.

With 'heart attack season' approaching, the sweet fruit could be a boon for Americans' health.

New research finds that people who don't like music might have lower blood flow in certain parts of their brains.

Scientists have found structures that resemble an emu's red blood cells, and others that look like collagen, inside 75 million-year-old dinosaur bones.

This traditional beverage has many health benefits, including a possible blood sugar lowering effect.

Did you know that specific foods could help maintain healthy blood sugar levels? Here are 6 of them.

Tattoo may provide an inexpensive and noninvasive method for testing blood sugar levels, without the finger prick.

High blood pressure is known as the silent killer — many people don't realize they have it until it’s too late.

James Harrison's plasma is used to make treatments for Rhesus disease. He has made 1,173 donations over more than 60 years, but now he has to retire.

We label a lot of species with the shiver-inducing denizen of the night, even if they don't suck blood.

Advocacy groups call the new recommendation arbitrary and discriminatory.

Scientists using artificial intelligence have devised a highly accurate blood test for 50 kinds of cancer by looking for the DNA of dead tumor cells.

Organic gardening brings benefits to both you and the plant

The beautiful, predatory moonfish can warm its own body, just like mammals and birds.

Canine blood banks provide a life-saving resource to man's best friend, but there has been controversy about some operations.

With millions of Americans staying home, blood donations are drying up. It's safe to give if you are healthy.

Blood snow not only looks sinister, it contributes to a feedback loop that accelerates warming.